VIP

Also known as Vasoactive Intestinal Peptide, Vasoactive Intestinal Polypeptide, Aviptadil, RLF-100, ZYESAMI

A 28-amino-acid neuropeptide and potent vasodilator/immune modulator; its synthetic form aviptadil has been studied in ARDS/COVID-19 and pulmonary arterial hypertension.

Molecular weight~3325 g/mol (28-residue peptide)

Half-lifeVery short — roughly 1–2 minutes in plasma, which limits both systemic accumulation and durability of effect.

CategoryOther

Typical use cases

✓ Anti-inflammatory/immune research✓ Pulmonary (ARDS/PAH) research via aviptadil✓ CIRS support (anecdotal)✓ Vasodilation studies

Dosing guidelines

StartingResearch use is most often intranasal at microgram amounts (e.g. ~50 mcg per spray), titrated cautiously. Aviptadil clinical studies use controlled IV infusion under medical supervision.

MaintenanceIntranasal research protocols commonly describe several mcg-to-~50 mcg doses one or more times daily; subcutaneous is also used. No standardized consumer regimen exists.

Max (studied)No validated research upper bound; hedge. Given vasodilation and a very short half-life, doses are kept low and watched for blood-pressure effects.

Titration

Typically started low (intranasal) and increased gradually; aviptadil clinical dosing is fixed-protocol IV, not self-titrated.

Reconstitution

Commonly sold as a ~6 mg lyophilized vial; reconstitute with bacteriostatic water and, for intranasal use, transfer to a nasal spray/dropper at the target concentration.

Injection sites

Most research use is intranasal; subcutaneous (abdomen/flank) is also described. The synthetic aviptadil form is given as IV infusion in clinical trials.

Storage & handling

Lyophilized: stable months cool/dark, longer frozen. Reconstituted: refrigerate (2–8 °C).

Side effects

Flushing Mild · Common
Hypotension / lightheadedness Moderate · Uncommon
Diarrhea / GI upset Mild · Uncommon
Nasal irritation (intranasal) Mild · Uncommon

Research summary

VIP is a glucagon/secretin-superfamily neuropeptide acting at VPAC1/VPAC2 receptors to raise cAMP, producing vasodilation, smooth-muscle relaxation, and anti-inflammatory effects; it has a very short (~1–2 min) plasma half-life. Its synthetic analog aviptadil (RLF-100/ZYESAMI) received FDA fast-track and orphan-drug designations and was studied in COVID-19-associated ARDS and pulmonary arterial hypertension, with mixed/inconclusive clinical results. In wellness circles intranasal VIP is used anecdotally for chronic inflammatory response syndrome (CIRS), but human evidence is limited; main concerns are hypotension, flushing, and diarrhea. Educational only — not medical advice.

Key references

Said & Mutt, Science (1970) — isolation/characterization of VIP
Youssef et al. (2021–2022) — aviptadil in severe COVID-19 ARDS clinical trial reports

Related compounds

KPV → LL-37 →

Where to buy

🛍 Core Peptides Third-party tested ↗

These are affiliate links. Purchasing through them helps support DoseForge at no extra cost to you.

Educational reference only — not medical advice. Dosing figures are commonly-cited ranges, not prescriptions. Consult a qualified clinician.

Track VIP in DoseForge

Log doses, rotate sites, watch your progress — free.

Get the app